Close Menu

Biodesix

Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.

Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.

BlueCross BlueShield of Florida began covering the test on March 15, and Health Care Services Corporation will begin coverage in June.

Norgen Biotek's sample prep  products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.

The company said it will use the funds to continue developing new companion diagnostics and expand commercialization of its VeriStrat and GeneStrat products

The company last year launched a PCR-based assay for identifying mutations in lung cancer patients and plans to release an NGS-based test later this year.

In a study looking at a total of 149 subjects with advanced unresectable melanoma, the test proved useful for distinguishing between good and poor responders.

Biodesix Raises $8.6M

The Colorado-based cancer diagnostics firm said in an SEC document that it seeks to raise up to $20 million.

The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.